NaCl. Glucose. to h before treatment and ml NaCl. Glucose. h after cisplatin infusion. To determine the effect of tipifarnib on the pharmacokinetics of gemcitabine and cisplatin, 2-Methoxyestradiol administration of this agent has been distributed the days of the cycle. Dose escalation was used under mg bid tipifarnib with gemcitabine and cisplatin MGM MGM. At least three patients were treated at each dose. If DLT patients wa W While the cycle is concerned, three patients were included in this cohort. MTD was defined, in which one or more of the patients have DLT X. Dose-limiting toxicity t was toxicity T T tt defined Xgrade Drogenkriminalit nonhaematological He nausea and vomiting associated with untreated day t granulocytopenia lasting quality t, or an infection with thrombocytopenia fever, tipifarnib treatment interruption for several days because of the associated toxicity t Neurotoxizit t and t or Ototoxizit X Class, Ma no or at least a few weeks has improved.
This toxicity E t was visible when DLT occurred w W During the first treatment cycle. In the case of the h-th degree dermatologic toxicity Gemcitabine dose was t n N Chster cycle over Blutk rperchen low. Dose adjustments were with the initial BIBW2992 dose of gemcitabine U in the previous cycle of therapy report back. Expected if the nadir granulocyte ml and the nadir platelet count was administered ml dose of gemcitabine. When was the low point of granulocytes per ml or nadir platelets per ml, the dose of gemcitabine administered expected. The dose of cisplatin was not due to toxicity T Th wh dermatological W During the previous cycle experience reduced.
The administration of tipifarnib was discontinued, as dermatological h DLT occurred. After the recovery of at least t Tipifarnib was at the same dose in combination with a Change the dose of restored gemcitabine. Is provided when a patient dermatological h DLT reduced dose adjustment of the dose of gemcitabine tracking mg bid tipifarnib If at any time the tipifarnib dose o mg bid or if a repeat of the need to seat weeks after the restart delay Reduce delay cycle patient left study. In the event of toxicity T Tsgrad nonhaematological dose of gemcitabine and cisplatin once adjusted. Dose adjustment of the initial dose of gemcitabine and cisplatin were compared U re in the previous cycle. If the toxicity of t Degree produces nonhaematological century, patients were re-dose U.
If nonhaematological produces grade toxicity t, Patients went off study. Receive no dose adjustment for transaminases less FITTINGS with clinical signs or symptoms Made My Meas. If a DLT occurred or quality t Or Grade Nonhaematological Neurotoxizit ttt Ototoxizit was tipifarnib treatment until the toxicity t of t-gel interrupted at St degrees and has in the auditor’s judgment, constitute a Been change in the dose of cisplatin and gemcitabine again a reduction in the dose of mg bid tipifarnib was applied. If at any time the dose should be reduced tipifarnib o mg bid or if a repeat of the need galv week under siege after restarting a cycle, lose the patient study. Patients with progressive disease, he had